Moderna Inc. Q2 FY2026 Earnings Call Summary

MRNA NASDAQ Healthcare 📅 2026-07-31 ⏱ ~60 sec read 🟡 Neutral

⏱️ 60-Second Brief Moderna Inc. · Q2 FY2026

Revenue

$0.1B

EPS

$(1.97)

AI Sentiment

🟡 Neutral

The company showed improved financial discipline and pipelin…

📌 Bottom Line: Moderna reported a net loss of $(782) million and $(1.97) EPS on $145 million in revenue for Q2 2026, but improved its full-year operating expense outlook and anticipates potential approval for its seasonal influenza vac…

🤖 AI-Assisted Summary — Produced using a custom AI pipeline by Abhi, reviewed for accuracy. · ⚠️ Not financial advice. For informational purposes only. Full Disclaimer →

✍️ EarningsBloom Editorial Team · 📅 Last updated: 2026-08-02 · 📎 Source: SEC EDGAR / Company Press Release

📋 TL;DR — What Happened

Moderna reported a net loss of $(782) million and $(1.97) EPS on $145 million in revenue for Q2 2026, but improved its full-year operating expense outlook and anticipates potential approval for its seasonal influenza vaccine, mFLUSIVA. However, the company also announced a setback for its norovirus vaccine candidate, which failed to meet early success criteria in its Phase 3 interim analysis, requiring further enrollment.

📊 Key Financial Metrics

Revenue $0.1B

EPS (Diluted) $(1.97)

YoY Revenue Growth 2.1%

Gross Margin 35.9%

Net Income $(782M)

AI Sentiment 🟡 Neutral The company showed improved financial discipline and pipeline progress, but a significant setback in its norovirus vaccine program and continued net losses temper optimism.

✅ What Went Well

✅ Moderna significantly improved its 2026 GAAP operating expense outlook by approximately $0.2 billion and increased its projected year-end cash balance to $4.7 - $5.2 billion, also an improvement of $0.2 billion, demonstrating enhanced financial discipline and operational efficiency.

✅ The company is on track for a potential U.S. approval of its seasonal influenza vaccine candidate, mFLUSIVA (mRNA-1010), with an August 5th PDUFA date, which would diversify its product portfolio beyond COVID-19 vaccines and represent its fifth approved product.

✅ Positive five-year Phase 2b adjuvant melanoma data for intismeran (mRNA-4157) in combination with KEYTRUDA showed a compelling 49% reduction in the risk of recurrence or death, highlighting the strong potential of its oncology pipeline.

✅ Operational efficiencies led to a 22% year-over-year decrease in cost of sales to $93 million, contributing to a gross margin of 35.9% and a 5% improvement in net loss compared to the prior year.

⚠️ Concerns & Risks

⚠️ The Phase 3 interim analysis for mRNA-1403, Moderna’s norovirus vaccine candidate, did not meet statistical criteria for early success, necessitating the enrollment of an additional cohort, which introduces delays and uncertainty into this key pipeline program.

⚠️ Despite a slight improvement, the company reported a substantial net loss of $(782) million for the quarter, indicating that it remains unprofitable and heavily reliant on future pipeline successes to achieve sustained profitability.

⚠️ Lower COVID vaccine sales in the U.S. and South America were noted, highlighting the ongoing challenge of transitioning from pandemic-era demand to a more diversified and sustainable revenue base.

⚠️ Cash, cash equivalents, and investments decreased from $7.5 billion to $6.9 billion quarter-over-quarter, with a significant $950 million litigation settlement payment made in July 2026, indicating continued cash usage for operations and investments.

🔮 CEO / Management Guidance

Moderna reiterated its plan to deliver up to 10% revenue growth in 2026, with an improved GAAP operating expense outlook for the year, lowered by approximately $0.2 billion. The company also improved its expected 2026 year-end cash balance to $4.7 - $5.2 billion, an increase of about $0.2 billion from previous estimates. Management anticipates approximately 55% of its second half 2026 revenue to be recognized in the third quarter.

💬 Key Quote

The second quarter marked another period of strong execution for Moderna as we advanced our pipeline and strengthened our financial profile with an improved 2026 operating expense outlook. — Stéphane Bancel, Chief Executive Officer

📅 Quarter-over-Quarter Comparison

Comparing Q2 FY2026 vs Q4 FY2026 All quarters →

Revenue $0.7B → $0.1B

EPS $(7.26) → $(1.97)

Sentiment 🔴 Bearish → 🟡 Neutral

🏢 About Moderna Inc.

Moderna Inc. (MRNA) is a publicly listed company on the NASDAQ exchange in the Healthcare sector. EarningsBloom tracks its quarterly earnings calls to provide free AI-generated summaries for investors.

MRNA NASDAQ Healthcare All Moderna Inc. Summaries →

📈 Want to act on this insight?

🇮🇳 Open Zerodha Account 🌱 Start with Groww 📄 Full Transcript on Seeking Alpha 📚 Learn Financial Analysis

Topics: mRNA Vaccines Biotechnology Pharmaceuticals Clinical Trials

📁 More from Moderna Inc.

View all earnings summaries for Moderna Inc. →